NasdaqCM - Delayed Quote USD

Avalo Therapeutics, Inc. (AVTX)

10.60 -0.22 (-2.03%)
At close: May 14 at 4:00 PM EDT
10.60 0.00 (0.00%)
Pre-Market: 8:23 AM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Garry A. Neil M.D. Chairman of the Board, President & CEO 475k -- 1954
Mr. Christopher Ryan Sullivan CFO & Head of Investor relations 350k -- 1984
Dr. Solomon H. Snyder M.D. Founder and Chairman of Scientific Advisory Board -- -- 1939
Dr. Barbara S. Slusher Ph.D. Founder and Member of Scientific Advisory Board -- -- 1965
Dr. Lisa Hegg Ph.D. Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations -- -- --
Ms. Colleen Matkowski Senior Vice President of Global Regulatory Affairs & Quality Assurance -- -- --
Dr. Dino C. Miano Ph.D. Senior Vice President of CMC & Technical Operations -- -- --

Avalo Therapeutics, Inc.

540 Gaither Road
Suite 400
Rockville, MD 20850
United States
410-522-8707 https://www.avalotx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
19

Description

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Corporate Governance

Avalo Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Aug 01, 2024 - Aug 05, 2024
Avalo Therapeutics, Inc. Earnings Call

Related Tickers

BDRX Biodexa Pharmaceuticals Plc
1.1000
+13.99%
 
ALLR Allarity Therapeutics, Inc.
0.7885
-0.94%
 
TPST Tempest Therapeutics, Inc.
3.4000
+3.66%
 
PXMD PaxMedica, Inc.
0.2070
-9.53%
 
IBIO iBio, Inc.
1.8800
+3.56%
 
TCBP TC Biopharm (Holdings) Plc
1.1500
+1.77%
 
ADIL Adial Pharmaceuticals, Inc.
1.4400
-0.35%
 
CDIO Cardio Diagnostics Holdings, Inc.
0.8135
-9.11%
 
RNAZ TransCode Therapeutics, Inc.
0.7301
+18.48%
 
PALI Palisade Bio, Inc.
6.24
+0.32%